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Abstract
Background: Many studies have focused on the implication of the serotonin and dopamine
systems in neuroadaptive responses to the recreational drug 3,4-methylenedioxy-metamphetamine
(MDMA). Less attention has been given to the major excitatory neurotransmitter glutamate known
to be implicated in schizophrenia and drug addiction. The aim of the present study was to
investigate the effect of repeated intermittent MDMA administration upon gene-transcript
expression of the glutamate transporters (EAAT1, EAAT2-1, EAAT2-2), the glutamate receptor
subunits of AMPA (GluR1, GluR2, GluR3), the glutamate receptor subunits of NMDA (NR1, NR2A
and NR2B), as well as metabotropic glutamate receptors (mGluR1, mGluR2, mGluR3, mGluR5) in
six different brain regions. Adolescent male Sprague Dawley rats received MDMA at the doses of
3 × 1 and 3 × 5 mg/kg/day, or 3× vehicle 3 hours apart, every 7th day for 4 weeks. The gene-
transcript levels were assessed using real-time PCR validated with a range of housekeeping genes.
Results: The findings showed pronounced enhancements in gene-transcript expression of GluR2,
mGluR1, mGluR5, NR1, NR2A, NR2B, EAAT1, and EAAT2-2 in the cortex at bregma +1.6. In the
caudate putamen, mRNA levels of GluR3, NR2A, and NR2B receptor subunits were significantly
increased. In contrast, the gene-transcript expression of GluR1 was reduced in the hippocampus.
In the hypothalamus, there was a significant increase of GluR1, GluR3, mGluR1, and mGluR3 gene-
transcript expressions.
Conclusion:  Repeated intermittent MDMA administration induces neuroadaptive changes in
gene-transcript expressions of glutamatergic NMDA and AMPA receptor subunits, metabotropic
receptors and transporters in regions of the brain regulating reward-related associative learning,
cognition, and memory and neuro-endocrine functions.
Background
The recreational drug 3,4-methylenedioxy-metampheta-
mine (MDMA; ecstasy) is popular among young people
due to its energy and mood enhancing properties [1].
MDMA abuse is also associated with psychiatric side effect
such as hallucinations, depression, reduced cognitive per-
Published: 17 April 2008
BMC Neuroscience 2008, 9:39 doi:10.1186/1471-2202-9-39
Received: 18 December 2007
Accepted: 17 April 2008
This article is available from: http://www.biomedcentral.com/1471-2202/9/39
© 2008 Kindlundh-Högberg et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2008, 9:39 http://www.biomedcentral.com/1471-2202/9/39
Page 2 of 10
(page number not for citation purposes)
formance and memory loss [2-6]. The various actions and
effects of MDMA have resulted in contradictive views
among researchers regarding the degree of the harmful-
ness of the drug [7]. Many studies have focused on neu-
roadaptive responses in the serotonin and dopamine
systems towards MDMA [8,9]. However, in order to
achieve a comprehensive picture of neurobiochemical
mechanisms underlying MDMA induced psychiatric
changes, research on MDMA to a higher extent also has to
be extended to include closely interacting systems.
The major excitatory neurotransmitter in the CNS is the
glutamate system [10]. It is interactive with GABA,
dopamine and serotonin, especially through the regula-
tion of the corticofugal neuronal activity between the fore-
brain cortex and subcortical brain regions [11-15]. In
addition to being implicated in learning plasticity and
neural cell death [16], the glutamate system is implicated
in addictive diseases to several drugs of abuse [14,17-19],
as well as psychiatric conditions such as e.g. schizophre-
nia [13,14]. Nevertheless, only a few studies have been
performed on MDMA and glutamate. Microiontophoretic
application of MDMA has been shown to inhibit gluta-
mate evoked firing of most cells in the nucleus accumbens
[20], possibly through the drug mediated release of
dopamine and serotonin [21]. The glutamatergic NMDA
antagonist MK801 has been shown to protect against
MDMA caused serotonin depletion and tryptophanehy-
droxylase decrease [22,23]. Moreover, ACEA (glycine site-
specific antagonist 5-nitro-6,7-dichloro-2,3-quinoxaline-
dione) is shown to counteract MDMA induced 5HT deple-
tion and decrease in paroxetin binding [24]. NMDA
receptors are possibly implicated in MDMA mediated
mechanisms. However, the specific roles of glutamate and
its receptors in response to MDMA administration are not
well evaluated. In particular, knowledge of glutamatergic
gene-transcript regulation following MDMA administra-
tion is limited.
The aim of the present study was to investigate the imme-
diate effects of repeated intermittent MDMA administra-
tion upon gene-transcript levels of glutamatergic receptors
and transporters. The mRNA levels of glutamate transport-
ers (EAAT1, EAAT2-1, EAAT2-2), AMPA receptor subunits
(GluR1, GluR2, GluR3), NMDA receptor subunits (NR1,
NR2A and NR2B), as well as metabotropic glutamate
receptors (mGluR1, mGluR2, mGluR3, mGluR5) were
confirmed in six regions of the male rat brain (the pre-
frontal cortex (PFC), cortex, caudate putamen (CPU),
nucleus accumbens (Acb), hippocampus and hypothala-
mus. These brain regions are known to be important for
psychiatric conditions associated with MDMA abuse.
Methods
Animal treatment
Male adolescent Sprague-Dawley rats (weighing 216 ± 13
g and aged 7 weeks; Alab, Sollentuna, Sweden) were ran-
domly separated into two MDMA ((±)-3,4-methylenedi-
oxy-N-methamphetamine-HCl, Sigma Pharmaceutical)-
treated groups and one control group. The rats were
housed pair wise in air-conditioned rooms (12-h dark/
light cycle) at 20°C and a humidity of 53%. All animals
were subjected to one day of treatment every 7:th day for
4 weeks. On the drug-treatment day the animals received
3 intra-peritoneal injections given 3 hours apart (a binge);
the MDMA low dose rats (n = 8) received 3 × 1 mg/kg
MDMA, the MDMA high dose rats (n = 8) 3 × 5 mg/kg,
whereas the controls received the vehicle of sterile 0.9%
saline solution (1 ml/kg). The MDMA was dissolved into
the vehicle on the day of testing. The rationale for these
MDMA doses stems from human conditions, and has
been presented elsewhere [25]. The performed experi-
ments are approved by the local ethical committee in
Stockholm, Sweden (N164/04) and are in agreement with
international guidelines on the ethical use of animals.
This ensures that the number of animals was minimized
and the handlings monitored to avoid suffering. All rats
were decapitated 10 h after the first injection of the last
4th MDMA binge to avoid withdrawal effects and study
the immediate effects of repeated intermittent MDMA
treatment.
Brain regions of interest (the prefrontal cortex (PFC), cor-
tex at bregma +1.6 to +0.7 (cortex bregma +1.6) including
cingulate cortex, primary motor cortex, and secondary
motor cortex, caudate putamen (CPU), Acb (Acb), hip-
pocampus (at bregma -4.8 to -5.6), and the hypothalamus
(arcuate nucleus, ventromedial hypothalamus and partly
the paraventricular nucleus) were dissected using a rat
brain matrix [26], rapidly frozen on dry ice, immersed
into RNA later (Ambion) for 1 hour, and then stored at –
80°C.
Isolation of total RNA and reverse-transcription PCR
Total RNA was isolated from individual brain regions by
phenol-chloroform extraction. Tissue samples (<100 mg)
were homogenised in 500 µl TRIZOL (Invitrogen) by ultra
sonication with a Branson sonifier. 100 µl chloroform was
added. The homogenate was centrifuged at 10 000 rpm
for 20 minutes. The RNA of the water-soluble supernatant
was precipitated with isopropanol, and washed twice with
ethanol, 75% and 80%, respectively. The air dried RNA
pellet was dissolved in RNAase free water. DNAase
(Roche) treatment was performed at 37°C for 3 hours in
order to remove DNA contamination, followed by inacti-
vation of the enzyme at 75°C for 15 minutes. The RNA
purity was validated by polymerase chain reaction (PCR)
and gel-electrophoresis using primers for a 300 bp cDNABMC Neuroscience 2008, 9:39 http://www.biomedcentral.com/1471-2202/9/39
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of GAPDH (NM017008: tcc ctc aag att gtc agc aa; cac cac
ctt ctt gat gtc atc). Total RNA concentration was deter-
mined using a nanodrop and was reverse transcribed
using random primers, pd(N)6, according to manufactur-
ers protocol (Amersham Biotech, Sweden). The cDNA
synthesis was evaluated by PCR and gel-electrophoresis.
Real Time PCR
The mRNA content of the various brain regions was
assessed by real time PCR (quantitative PCR, qPCR) in
terms of relative quantifications of amplified cDNA of
interest using iCykler (Bio-Rad Laboratories, Sundbyberg,
Sweden). The qPCR was performed in a final reaction vol-
ume of 20 µl. The concentration of templates consisting of
synthesised cDNA was 1.25 ng/µl. The cDNA correspond-
ing to transcripts of interest was identified by primers (see
below) at a concentration of 0.8 pmol/µl for each of the
sense and antisense, respectively.
In addition to template and primers, the qPCR reaction
also contained 20 mM Tris/HCl (pH 8.4), 50 mM KCl, 4
mM MgCl2, 0.16 mM dNTP, SYBR Green (1:50,000), as
well as Taq DNA polymerase (Invitrogen) at 0.02 U/µl. All
qPCR experiments were performed in either triplicates or
duplicates of each brain-tissue-cDNA template on an indi-
vidual basis (n = 8/group). A negative control using water
as template was included for each primer pair. For the
qPCR protocol, annealing temperatures were between
58–62°C (depending on primer pair) and 50 cycles were
used. Melting curves were included to confirm that only a
single product was performed.
Primers used for qPCR
Primers of used house-keeping genes (HKG) β-actin (ACT;
NM_031144; cac tgc cgc atc ctc ttc ct; aac cgc tca ttg ccg ata
gtg), cyclophilin (CYCLO; M19533; gag cgt ttt ggg tcc agg
aat; aat gcc cgc aag tca aag aaa), glyceraldehyde-3-phos-
phate-dehydrogenase (GAPDH; X02231; aca tgc cgc ctg
gag aaa cct; gcc cag gat gcc ctt tag tgg), histone H3b (H3b;
NM_053985; att cgc aag ctc ccc ttt cag; tgg aag cgc agg tct
gtt ttg), ribosomal protein-19 (RP19; NM:031103; tcg cca
atg cca act ctc gtc; agc ccg gga atg gac agt cac), β-tubulin,
beta 5 (TUB; NM_173102; cgg aag gag gcg gag agc; agg gtg
ccc atg cca gag c), and succinate dehydrogenase complex A
subunit A (SDHA; ggg agt gcc gtg gtg tca ttg; ttc gcc cat agc
ccc cag tag) have previously been validated [27]. Primers
of investigated gene transcripts of interest were designed
with Beacon Designer (v2.1/v4.0) as follows: AMPA
receptor subunits GluR1(NM_031608: caa cca ccg agg aag
gat acc; ttc aca gtca acc acc acc ag), GluR2 (AF164344: ttg
tga gga cta ccg cag aag; gga ctc cag caa gta ggc atac), GluR3
(NM_032990: gtt aca aat cac ggg cag ag tc; tgg cag gag cag
gct taa ag); NMDA subunits NR1 (ctg caa ccc tca cttt tgag;
tgc aaa agc cag ctg cat ct) (common to all splice variants)
[28], NR2A (cag cag caa gcc aca gtt atg; agt ctc ggt agc cag
gga ag), NR2B (caa gaa cat ggc caa cct gt; ggt aca cat tgc tgt
cct tc) [28], metabotropic receptors mGluR1
(NM_017011: gcc acc aca cca cct ctg; tga cgg aat cag cca gga
ac), mGluR2 (XM_001073809: ttg tgc gtg cct cac tcag; ctg
tag gag cat cac tgt gg), mGluR3 (atg gtg tcc gtg tgg ctt atc;
tga ctg ttt ccc gct tct ctg), mGluR5 (NM_017012: tgt cca cca
cca acc aac tg; gcc tcc act ctc tga atc cc); glutamate trans-
porters EAAT1/GLAST (NM_019225:tct cct cta ctt cct ggt
aac; agg gtg gca gaa ctt gag), EAAT2-1/Glt1a (NM_017215/
AY069978: gag gaa gaa cct tgg aaa cg; gga agc ctg ttt aga gca
tc), EAAT 2-2/Glt1b (NM_001035233: AF451299: ttg ctt
gtt tca cca gat tcc; gcc atc aaa gtt ctg aca acc). The Basic
Local Alignment Search Tool (BLAST) from the National
Center for Biotechnology Information (NCBI) was
applied to ensure that all amplified sequences shared no
homology and were different from any other cDNA in the
database.
Evaluation of housekeeping genes and data analysis
The iCycler v3.0 Software for windows was used to ana-
lyse qPCR data, selected as cycle numbers, which for each
plate-set-up both were normalized to the highest cDNA
sample amount (lowest Ct value) and corrected according
to a formula developed by Pfaffl and Co-workers of which
the efficiency was calculated by means of the program Lin-
Reg [29]. Relative cycle numbers of investigated gene-tran-
script levels were normalized by normalization factors
based on the inclusion of multiple HKGs as reference
genes [30]. The approach of using multiple HKGs instead
of one single ensures a much more accurate quantification
of the content of gene transcript expression. A visual basic
program, GeNorm (provided by Vandesompele) was
applied to evaluate which unique set of HKGs that was the
most stable in terms of a gene-stability measure for a given
set of samples (cDNA batches of the current treatment
profile including all three investigated groups) of each
particular brain region. This methodology has been
described elsewhere [25,30].
Statistics
Statistical analyses were conducted with Statview
(Statview v.5.0 for Windows). Shapiro-Wilk's test was
applied to analyse the Gaussian distribution. One-way
ANOVA and Fischer's PLSD test were used for statistical
analyses of relative gene-transcript levels.
Results
The set of HKGs with the most stable gene-stability value
for a particular brain region have previously been pre-
sented [25]. For each brain region 7 HKGs were run by
qPCR. In the PFC 5 HKGs were evaluated to be the most
stable (GAPDH, RP19, SDHA, H3b, CYCLO), in the cor-
tex 3 HKGs (β-actin, GAPDH, RP19), CPU (GAPDH,
RP19, TUB, H3b), Acb (β-actin, GAPDH, TUB, SDHA,
H3b, CYCLO), hippocampus (β-actin, RP19, TUB, H3b),BMC Neuroscience 2008, 9:39 http://www.biomedcentral.com/1471-2202/9/39
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amygdala (β-actin, GAPDH, RP19, TUB, SDHA, CYCLO),
and hypothalamus (β-actin, GAPDH, TUB, SDHA, H3b,
CYCLO) [25].
The effects of repeated intermittent MDMA administra-
tion, 3 × 1 mg/kg (MDMA low) or 3 × 5 mg/kg (MDMA
high), every 7th day for 4 weeks are presented as relative
mRNA expressions in percent of the relative cycle num-
bers for controls, Figure 1 and 2. There were no significant
alterations in the PFC, Figure 1A. The findings of ANOVA
evaluated F-statistics and P-values presented as (mean ±
SEM) for investigated mRNA levels in the PFC are as fol-
lows: GluR1 mRNA (F(2,20) = 1.05; P-value = 0.155):
controls (100.0 ± 13), MDMA low (79.0 ± 7), and MDMA
high (76.9 ± 6); GluR2 mRNA (F(2,21) = 2.08; P-value =
0.137): controls (100.0 ± 12), MDMA low (94.9 ± 11),
and MDMA high (71.6 ± 7); GluR3 mRNA (F(2,20) =
2.10; P-value = 0.149): controls (100.0 ± 13), MDMA low
(91.5 ± 11), and MDMA high (69.9 ± 8); mGluR1 mRNA
(F(2,20) = 3.08; P-value = 0.201): controls (100.0 ± 20),
MDMA low (57.9 ± 9), and MDMA high (84.9 ± 15);
mGluR2 mRNA (F(2,17) = 1.03; P-value = 0.379): con-
trols (100.0 ± 13), MDMA low (95.6 ± 18), and MDMA
high (74.0 ± 13); mGluR3 mRNA (F(2,21) = 0.89; P-value
= 0.740): controls (100.0 ± 8), MDMA low (88.1 ± 8), and
MDMA high (83.2 ± 11); mGluR5 mRNA levels (F(2,20)
= 1.33; P-value = 0.286); controls (100.0 ± 8), MDMA low
(75.2 ± 14), and MDMA high (87.6 ± 10); NR1 mRNA
(F(2,20) = 1.06; P-value = 0.365): controls (100.0 ± 10),
MDMA low (135.7 ± 25), and MDMA high (110.5 ± 16);
NR2A mRNA (F(2,19) = 0.82; P-value = 0.454): controls
(100.0 ± 14), MDMA low (136.7 ± 28), and MDMA high
(113.5 ± 16); NR2B mRNA (F(2,20) = 1.86; P-value =
0.181): controls (100.0 ± 18), MDMA low (163.4 ± 30),
and MDMA high (133.1 ± 21); EAAT1 mRNA (F(2,19) =
1.17; P-value = 0.333): controls (100.0 ± 9), MDMA low
(90.6 ± 14), and MDMA high (115.1 ± 12); EAAT2-1
mRNA (F(2,19) = 0.20; P-value = 0.817) controls (100.0
± 14), MDMA low (111.7 ± 19), MDMA high (113.0 ±
17); EAAT2-2 mRNA (F(2,18) = 0.80; P-value = 0.463):
controls (100.0 ± 17), MDMA low (144.5 ± 29), and
MDMA high (119.0 ± 25).
In the cortex (bregma +1.6), MDMA high caused signifi-
cant neuroadaptive enhancements of mRNA levels com-
pared to controls for the AMPA subunit GluR2, the NMDA
receptor subunits NR1, NR2A, and NR2B, the metabo-
tropic receptors mGluR1 and mGluR5, as well as the
glutamate transporters EAAT1 and EAAT2-2, Figure 1B.
The findings of ANOVA analysis are as follows: GluR1
mRNA (F(2,15) = 1.93; P-value = 0.179): controls (100.0
± 10), MDMA low (134.7 ± 30), and MDMA high (178.3
± 29); GluR2 mRNA (F(2,15) = 11.73; P-value < 0.001):
controls (100.0 ± 15), MDMA low (110.7 ± 12), and
MDMA high (186.9 ± 15); GluR3 mRNA (F(2,20) = 0.15;
P-value = 0.270): controls (100.0 ± 17), MDMA low
(106.8 ± 14), and MDMA high (138.2 ± 20); mGluR1
mRNA (F(2,17) = 16.22; P-value < 0.001): controls (100.0
± 10), MDMA low (129.5 ± 28), and MDMA high (235.0
± 13), mGluR2 mRNA (F(2,18) = 1.40; P-value = 0.272):
controls (100.0 ± 14), MDMA low (158.0 ± 55), and
MDMA high (189.1 ± 48); mGluR3 mRNA (F(2,19) =
1.61; P-value = 0.073): controls (100.0 ± 7), MDMA low
(88.8 ± 13), and MDMA high (129.0 ± 15); mGluR5
mRNA (F(2,18) = 5.72; P-value = 0.012): controls (100.0
± 6), MDMA low (93.4 ± 14), and MDMA high (156.6 ±
22); NR1 mRNA (F(2,20) = 6.24; P-value = 0.008): con-
trols (100.0 ± 16), MDMA low (159.5 ± 50), and MDMA
high (334.0 ± 68); NR2A mRNA (F(2,17) = 8.08; P-value
= 0.003): controls (100.0 ± 18), MDMA low (101.9 ± 18),
and MDMA high (216.8 ± 31); NR2B mRNA (F(2,20) =
9.14; P-value = 0.002): controls (100.0 ± 16), MDMA low
(141.8 ± 24), and MDMA high (276.8 ± 44); EAAT1
mRNA (F(2,18) = 19.0; P-value < 0.001): controls (100.0
± 10), MDMA low (108.5 ± 17), and MDMA high (241.8
± 26); EAAT2-1 mRNA (F(2,19) = 2.22; P-value = 0.136):
controls (100.0 ± 15), MDMA low (105.2 ± 24), and
MDMA high (147.0 ± 16); EAAT2-2 mRNA (F(2,19) =
6.71; P-value = 0.006): controls (100.0 ± 18), MDMA low
(73.5 ± 10), and MDMA high (156.9 ± 17).
In the CPU, MDMA high significantly enhanced mRNA
levels of the AMPA subunit GluR3, NMDA subunits NR2A
and NR2B, Figure 1C. The findings are as follows: GluR1
mRNA (F(2,21) = 2.16; P-value = 0.140): controls (100.0
± 8), MDMA low (88.9 ± 10), and MDMA high (115.5 ±
9); GluR2 mRNA (F(2,19) = 3.13; P-value = 0.067): con-
trols (100.0 ± 10), MDMA low (76.9 ± 7), and MDMA
high (105.1 ± 9); GluR3 mRNA (F(2,20) = 7.32; P-value =
0.004): controls (100.0 ± 6), MDMA low (83.8 ± 6), and
MDMA high (138.2 ± 15); mGluR1 mRNA (F(2,17) =
1.01; P-value = 0.383): controls (100.0 ± 5), MDMA low
(109.7 ± 15), and MDMA high (126.3 ± 12); mGluR2
mRNA (F(2,18) = 1.02; P-value = 0.382): controls (100.0
± 12), MDMA low (78.0 ± 13), and MDMA high (119.5 ±
23); mGluR3 mRNA (F(2,19) = 0.59; P-value = 0.562):
controls (100.0 ± 4), MDMA low (85.1 ± 11), and MDMA
high (99.5 ± 16); mGluR5 mRNA (F(2,20) = 3.07; P-value
= 0.061): controls (100.0 ± 5), MDMA low (71.4 ± 10),
and MDMA high (80.6 ± 9); NR1 mRNA (F(2,20) = 1.31;
P-value = 0.292): controls (100.0 ± 8), MDMA low (84.7
± 7), and MDMA high (105.1 ± 12); NR2A mRNA
(F(2,20) = 9.03; P-value = 0.002): controls (100.0 ± 9),
MDMA low (75.4 ± 10), and MDMA high (132.5 ± 10);
NR2B mRNA (F(2,17) = 13.59; P-value < 0.001): controls
(100.0 ± 10), MDMA low (68.4 ± 6), and MDMA high
(145.3 ± 13); EAAT1 mRNA (F(2,20) = 1.36; P-value =
0.285): controls (100.0 ± 17), MDMA low (134.6 ± 27),
and MDMA high (160.3 ± 30); EAAT2-1 mRNA (F(2,19)
= 0.42; P-value = 0.661): controls (100.0 ± 15), MDMABMC Neuroscience 2008, 9:39 http://www.biomedcentral.com/1471-2202/9/39
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Relative mRNA levels are presented in percent of relative cycle numbers for controls in response to repeated intermittent  MDMA administration. A) PFC, B) Cortex, C) CPU Figure 1
Relative mRNA levels are presented in percent of relative cycle numbers for controls in response to repeated 
intermittent MDMA administration. A) PFC, B) Cortex, C) CPU. Statistical analysis: Fischer's PLSD test was used for 
pair-wise analysis between independent groups in gene-transcripts where ANOVA analysis was considered to meet signifi-
cance. Presented significance levels are related to control according to Fischer's PLSD: *P < 0.05, **P < 0.01, ***P < 0.001.
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Relative mRNA levels are presented in percent of relative cycle numbers for controls in response to repeated intermittent  MDMA administration. A) Acb, B) Hippocampus, C) Hypothalamus Figure 2
Relative mRNA levels are presented in percent of relative cycle numbers for controls in response to repeated 
intermittent MDMA administration. A) Acb, B) Hippocampus, C) Hypothalamus. Statistical analysis: Fischer's PLSD 
test was used for pair-wise analysis between independent groups in gene-transcripts where ANOVA analysis was considered to 
meet significance. Presented significance levels are related to control according to Fischer's PLSD: *P < 0.05, **P < 0.01, ***P < 
0.001.
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low (98.0 ± 12), and MDMA high (123.8 ± 31); EAAT2-2
mRNA (F(2,20) = 1.24; P-value = 0.310): controls (100.0
± 10), MDMA low (86.4 ± 8), and MDMA high (112.0 ±
14).
In the Acb, there were no significant alterations observed,
Figure 2A. Findings showed; GluR1 mRNA (F(2,19) =
0.40; P-value = 0.977): controls (100.0 ± 11), MDMA low
(98.2 ± 6), and MDMA high (101.5 ± 13); GluR2 mRNA
(F(2,19) = 0.98; P-value = 0.591): controls (100.0 ± 9),
MDMA low (89.7 ± 10), and MDMA high (88.9 ± 6);
GluR3 mRNA (F(2,19) = 0.47; P-value = 0.632): controls
(100.0 ± 16), MDMA low (87.9 ± 12), and MDMA high
(82.2 ± 11); mGluR1 mRNA (F(2,19) = 0.41; P-value =
0.672): controls (100.0 ± 11), MDMA low (91.9 ± 8), and
MDMA high (88.5 ± 8); mGluR2 mRNA (F(2,19) = 1.16;
P-value = 0.336): controls (100.0 ± 15), MDMA low (76.7
± 8), and MDMA high (86.4 ± 7); mGluR3 mRNA
(F(2,20) = 0.56; P-value = 0.997): controls (100.0 ± 10),
MDMA low (98.9 ± 11), and MDMA high (100.0 ± 10)
mGluR5 mRNA (F(2,19) = 1.12; P-value = 0.348): con-
trols (100.0 ± 9), MDMA low (114.1 ± 9), and MDMA
high (97.0 ± 8); NR1 mRNA (F(2,20) = 1.58; P-value =
0.317): controls (100.0 ± 12), MDMA low (82.7 ± 11),
and MDMA high (79.8 ± 7); NR2A mRNA (F(2,19) = 1.01;
P-value = 0.385): controls (100.0 ± 13), MDMA low
(101.8 ± 12), and MDMA high (111.7 ± 14); NR2B mRNA
(F(2,19) = 0.38; P-value = 0.727): controls (100.0 ± 19),
MDMA low (123.8 ± 37), and MDMA high (129.0 ± 17);
EAAT1 mRNA (F(2,19) = 1.57; P-value = 0.234): controls
(100.0 ± 18), MDMA low (71.9 ± 11), and MDMA high
(109.5 ± 14); EAAT2-1 mRNA (F(2,19) = 2.10; P-value =
0.150): controls (100.0 ± 15), MDMA low (80.3 ± 13),
and MDMA high (60.8 ± 12); EAAT2-2 mRNA (F(2,20) =
1.85; P-value = 0.184): controls (100.0 ± 8), MDMA low
(73.1 ± 11), and MDMA high (95.9 ± 12).
In the hippocampus, the AMPA subunit GluR1 mRNA
was significantly decreased at the highest dose, Figure 2B.
GluR1 mRNA (F(2,18) = 10.60; P-value < 0.001): controls
(100.0 ± 5), MDMA low (80.4 ± 2), and MDMA high
(71.5 ± 5); GluR2 mRNA (F(2,20) = 0.32; P-value =
0.730): controls (100.0 ± 6), MDMA low (92.6 ± 6), and
MDMA high (98.8 ± 9); GluR3 mRNA (F(2,20) = 0.11; P-
value = 0.900): controls (100.0 ± 6), MDMA low (103.8 ±
9), and MDMA high (103.8 ± 5); mGluR1 mRNA (F(2,20)
= 1.84; P-value = 0.184): controls (100.0 ± 10), MDMA
low (85.4 ± 14), and MDMA high (123.0 ± 15); mGluR2
mRNA (F(2,16) = 1.27; P-value = 0.308): controls (100.0
± 12), MDMA low (91.6 ± 10), and MDMA high (121.1 ±
15); mGluR3 mRNA (F(2,19) = 0.69; P-value = 0.513):
controls (100.0 ± 9), MDMA low (113.1 ± 4), and MDMA
high (106.5 ± 7); mGluR5 mRNA (F(2,20) = 1.20; P-value
= 0.323): controls (100.0 ± 5), MDMA low (90.6 ± 7), and
MDMA high (86.9 ± 6); NR1 mRNA (F(2,19) = 0.34; P-
value = 0.714): controls (100.0 ± 15), MDMA low (105.3
± 10), and MDMA high (113.2 ± 5); NR2A mRNA
(F(2,20) = 0.43; P-value = 0.655): controls (100.0 ± 15),
MDMA low (94.5 ± 14), and MDMA high (114.0 ± 16);
NR2B mRNA (F(2,19) = 2.05; P-value = 0.156): controls
(100.0 ± 14), MDMA low (81.6 ± 11), and MDMA high
(126.1 ± 18); EAAT1 mRNA (F(2,19) = 1.34; P-value =
0.284): controls (100.0 ± 12), MDMA low (77.8 ± 8), and
MDMA high (110.1 ± 16); EAAT2-1 mRNA (F(2,20) =
1.47; P-value = 0.254): controls (100.0 ± 17), MDMA low
(74.9 ± 7), and MDMA high (103.2 ± 10); EAAT2-2
mRNA (F(2,18) = 0.99; P-value = 0.391): controls (100.0
± 9),, MDMA low (82.5 ± 10), and MDMA high (100.2 ±
10).
In the hypothalamus, the mRNA levels of GluR1, GluR3,
mGluR1, mGluR3 and NR1 were significantly increased
also after the administration of the highest MDMA dose,
Figure 2C. In the same region, NR2A mRNA was signifi-
cantly increased after repeated intermittent MDMA
administration at a dose of 3 × 1 mg/kg, Figure 1D. GluR1
(F(2,20) = 3.92; P-value = 0.036): controls (100.0 ± 9),
MDMA low (118.1 ± 12), and MDMA high (146.5 ± 13);
GluR2 mRNA (F(2,21) = 1.54; P-value = 0.239): controls
(100.0 ± 12), MDMA low (128.1 ± 16), and MDMA high
(151.5 ± 27); GluR3 mRNA (F(2,19) = 6.43; P-value =
0.007): controls (100.0 ± 8), MDMA low (108.9 ± 13),
and MDMA high (162.9 ± 17); mGluR1 mRNA (F(2,20) =
6.65; P-value = 0.006): controls (100.0 ± 6), MDMA low
(87.3 ± 16), and MDMA high (144.9 ± 9); mGluR2 mRNA
(F(2,16) = 1.12; P-value = 0.350): controls (100.0 ± 8),
MDMA low (114.0 ± 25), and MDMA high (134.1 ± 13);
mGluR3 mRNA (F(2,20) = 4.02; P-value = 0.034): con-
trols (100.0 ± 10), MDMA low (102.0 ± 11), and MDMA
high (137.4 ± 11); mGluR5 mRNA (F(2,21) = 0.41; P-
value = 0.669): controls (100.0 ± 14), MDMA low (100.0
± 9), and MDMA high (116.5 ± 19); NR1 mRNA (F(2,19)
= 5.30; P-value = 0.015): controls (100.0 ± 17), MDMA
low (97.5 ± 6), and MDMA high (151.5 ± 14); NR2A
mRNA (F(2,18) = 3.21; P-value = 0.064): controls (100.0
± 12), MDMA low (154.8 ± 14), and MDMA high (149.2
± 23); NR2B mRNA (F(2,19) = 2.05; P-value = 0.156):
controls (100.0 ± 13), MDMA low (83.9 ± 10), and
MDMA high (127.5 ± 25); EAAT1 mRNA (F(2,21) = 0.15;
P-value = 0.860): controls (100.0 ± 8), MDMA low (108.5
± 13), and MDMA high (101.4 ± 13); EAAT2-1 mRNA
(F(2,17) = 0.54; P-value = 0.594): controls (100.0 ± 15),
MDMA low (113.4 ± 16), and MDMA high (130.4 ± 30);
EAAT2-2 mRNA (F(2,18) = 3.12; P-value = 0.069): con-
trols (100.0 ± 11), MDMA low (107.2 ± 11), and MDMA
high (143.6 ± 16).
Discussion
The present study provides evidence that repeated inter-
mittent MDMA administration causes pronouncedBMC Neuroscience 2008, 9:39 http://www.biomedcentral.com/1471-2202/9/39
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changes in mRNA expression of certain glutamatergic
NMDA and AMPA receptor subunits, metabotropic recep-
tors and transporters in the forebrain cortex, CPU and the
hypothalamus. MDMA increased mRNA expression levels
of glutamatergic NMDA receptor subunits NR1, NR2A
and NR2B in the forebrain cortex, NR2A and 2B in the
CPU, and NR1 and NR2A (lower dose) in the hypothala-
mus. Since NMDA receptor antagonists are protective for
MDMA induced 5HT depletion and reduction of SERT
density [22,24], the current shown MDMA induced
enhancement in mRNA levels of glutamatergic NMDA
receptor subunits may contribute to MDMA mediated
neurotoxic effects. Furthermore, there are similarities
between the immediate effects of long-term MDMA
administration and other drugs of abuse. Repeated
cocaine administration is shown to enhance NMDA
receptor subunits in the VTA [31,32]. Chronic morphine
administration is shown to increase NR1 mRNA levels in
the hypothalamus [33]. Chronic alcohol administration is
known to produce increased NMDA receptor subunits in
response to suggested decreased glutamate levels [34-38].
Regarding glutamate transporters, EAAT1 (GLAST) and
EAAT2-2 (Glt1b/EAAT2b) (splice variant of EAAT2/Glt1)
were significantly increased at the highest administered
MDMA dose in the cortex. These glutamate transporters
play important roles in order to maintain extracellular
glutamate levels, mainly by being expressed on glial astro-
cytes [39,40]. Overactive glutamate transporters may
cause low glutamate levels. Taken together findings of
mRNA expression levels, both in NMDA receptor subnu-
nits and glutamate transporters, suggest low glutamate
levels in response to repeated intermittent MDMA admin-
istration.
Corticostriatal glutamatergic neurons projecting from the
forebrain cortex to sub-cortical brain regions in the CPU
and Acb regions are involved in the pathophysiology of
drug addiction and schizophrenia [41,42]. Reduced gluta-
matergic activity in this pathway is associated with psy-
chotic symptoms from drug abuse and schizophrenia
[43,44]. Interestingly, chronic haloperidol treatment
down regulate EAAT2 in the cingulate- and frontal cortex
in rats [45], indicating that decreased EAAT2 levels rather
may reflect a beneficial condition following the antipsy-
chotic treatment of schizophrenia. MDMA induced
enhancements in the EAAT 2-2 mRNA level in the fore-
brain cortex may therefore partly contribute to psychotic
effects of this drug.
Glutamatergic mRNA expression of AMPA receptor subu-
nits was also affected by repeated intermittent MDMA
administration. The mRNA level of GluR2 was increased
in the forebrain cortex, GluR3 in the CPU, and GluR1 and
GluR3 in the hypothalamus. In the forebrain cortex, gluta-
mate mediated activation of AMPA-KA receptors, either
localised on 5-HT nerve terminals or cortifugal glutama-
tergic pyramidal neurons projecting to the dorsal raphe
nucleus, is in turn suggested to enhance 5HT release via
stimulation of 5HT2A receptors [46]. Hallucinogenic drugs
such as DOI and LSD are interestingly suggested to acti-
vate 5HT2-receptors on GABA neurons in the cortex with
a strengthened inhibitory effect upon cortiostriatal gluta-
mate neurons to follow. This view is in agreement with
the fact that the initial MDMA mediated increase of
dopamine- and serotonin neurotransmission [21], inhib-
its glutamate evoked firing in the nucleus accumbens [20].
In our previous study, the 5HT2A receptor mRNA was sig-
nificantly reduced, whereas the 5HT2C receptor mRNA was
enhanced after repeated intermittent MDMA administra-
tion [25], indicating on compensatory mechanisms in
response to long term MDMA administration. Findings of
our current study may explain psychotic and hallucino-
genic symptoms from repeated intermittent MDMA
administration. However, some corticofugal glutamate
pathways are implicated circuits accelerating and other in
breaking the activity of subcortical systems in sophisti-
cated interplay [13].
In the hippocampus GluR1 mRNA was significantly
decreased. This brain region is important for the regula-
tion of cognitive functions and memory. Interestingly,
GluR1 is known to be implicated in memory functions
[47] and may play a role in MDMA induced cognitive def-
icits [2,48,49]. Memory loss in response to MDMA is pre-
viously reported to be caused by prevented learning
specific increase in NMDA NR1 expression and Ca2+/cal-
modulin-dependent protein kinase II (CaMKII) posphor-
ylation by reduced scaffolding postsynaptic density
protein PSD-95 levels, instead of direct effects by reduced
5HT activity itself [50,51]. However, in the hippocampus
repeated intermittent MDMA administration did not
cause any changes in mRNA levels of serotonin receptors
[25], nor NMDA subunits, indicating that other mecha-
nisms, here, primarily underlie potential MDMA elicited
memory deficits. This is additional support for the diver-
sity of studies on MDMA induced memory dysfunctions
[52].
In the hypothalamus, metabotropic mGluR1 and
mGluR3 receptors were also increased in addition to pre-
viously described findings of elevated mRNA levels in
glutamatergic AMPA and NMDA subunits. Neuroadaptive
alterations in the hypothalamus could reflect involvement
of numerous different mechanisms regulating neurendo-
crine functions, as well as motivational drives towards
feeding behaviour and rewarding properties of the corti-
costriatal-hypothalamic-brainstem network [53-55].
There were no significant changes in any of the investi-
gated glutamatergic gene-transcipts in the Acb in responseBMC Neuroscience 2008, 9:39 http://www.biomedcentral.com/1471-2202/9/39
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to repeated intermittent MDMA administration. Since the
Acb is an interactive target between glutamatergic cortico-
striatal projections and mesolimbic dopamine neurons
[14], and well known to be implicated in compulsive drug
abuse [56,57], this finding is very interesting. Although
MDMA causes an immediate increase in dopamine release
in the Acb [58,59], it is suggested to possess a primary
action upon the serotonergic system in rats [9,25,60]. One
potential explanation to the absence in glutamatergic
mRNA changes in response to MDMA in the Acb might
therefore be that interactive processes between serotoner-
gic and glutamatergic systems, here, are less pronounced
than between dopaminergic and glutamatergic systems.
On the other hand, taking into account that mRNA
expression of serotonin receptors also is reported to be
more extensive in the cortex than other brain areas in
response to repeated intermittent MDMA administration
[25], it is tempting to hypothesize that MDMA rather is
implicated in cognitive, associative, and hallucinogenic
responses than reward-related craving or incentive sali-
ence attribution [61,62]. Furthermore, future studies have
to achieve increased knowledge of the glutamatergic inter-
actions with the GABA and serotonergic activites in the
forebrain cortex [13], in order to better understand
MDMA induced responses. Furthermore, the posttran-
scriptional roles of glutamate-receptor subunits and gluta-
mate transporters also have to be fully evaluated.
Conclusion
Pronounced alterations of mRNA expression in glutamate
transporters, AMPA and NMDA receptor subunits in
regions of the adolescent male rat brain may contribute to
deficits in cognitions, memory and neuroendocrine func-
tions as well as hallucinations and psychosis from
repeated intermittent MDMA administrations.
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